Premium
Epigenetic alterations in metastatic cutaneous carcinoma
Author(s) -
Darr Owen A.,
Colacino Justin A.,
Tang Alice L.,
McHugh Jonathan B.,
Bellile Emily L.,
Bradford Carol R.,
Prince Mark P.,
Chepeha Douglas B.,
Rozek Laura S.,
Moyer Jeffrey S.
Publication year - 2015
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23701
Subject(s) - epigenetics , immunohistochemistry , basal cell carcinoma , pathology , skin cancer , metastasis , carcinoma , medicine , dna methylation , methylation , melanoma , cancer research , cancer , oncology , biology , basal cell , gene expression , biochemistry , gene
Background Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the 2 most common cutaneous carcinomas. Molecular profiles predicting metastasis of these cancers have not been identified. Methods Epigenetic profiles of 37 primary cases of cutaneous SCC and BCC were quantified via the Illumina Goldengate Cancer Panel. Differential protein expression by metastatic potential was analyzed in 110 total cases by immunohistochemical (IHC) staining. Results Unsupervised hierarchical clustering analysis revealed that metastatic BCCs had a methylation profile resembling cutaneous SCCs. Metastatic cutaneous SCCs were found to be hypermethylated at FRZB (median methylation: 46.7% vs 4.7%; p = 4 × 10 −5 ). Metastatic BCCs were found to be hypomethylated at MYCL2 (median methylation: 3.8% vs 83.4%; p = 1.9 × 10 −6 ). Immunohistochemical staining revealed few differences between metastatic and nonmetastatic cancers. Conclusion Metastatic primary BCCs and cutaneous SCCs had distinct epigenetic profiles when compared to their nonmetastatic counterparts. Epigenetic profiling may prove useful in future diagnosis and prevention of advanced nonmelanoma skin cancers. © 2014 Wiley Periodicals, Inc. Head Neck 37: 994–1001, 2015